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Abstract
Introduction: Pediatric severe sepsis (PSS) continues to be a major health problem. Extracorporeal therapies (ETs),
defined as extracorporeal membrane oxygenation (ECMO) and RRenal replacement therapyenal replacement
therapy (RRT), are becoming more available for utilization in a variety of health conditions. We aim to describe (1)
rates of utilization of ET in PSS, (2) outcomes for PSS patients receiving ET, and (3) epidemiologic characteristics of
patients receiving ET.
Methods: We conducted a retrospective review of a prospectively collected database. Data from the Pediatric
Health Information System (PHIS) database collected by the Children’s Hospital Association (CHA) from 2004–2012
from 43 US children’s hospitals’ pediatric intensive care units (PICUs) were used. Patients with PSS were defined by
(1) International Classification of Diseases, 9th Revision (ICD-9) codes reflecting severe sepsis and septic shock and
(2) ICD-9 codes of infection and organ dysfunction as defined by updated Angus criteria. Among the patients with
PSS, those with a PHIS flag of ECMO or RRT were identified further as our main cohort.
Results: From 2004 to 2012, 636,842 patients were identified from 43 hospitals, and PSS prevalence was 7.7 %
(49,153 patients). Nine point eight percent (4795 patients) received at least one form of ET, and the associated
mortality rate was 39 %. Mortality rates were 47.8 % for those who received ECMO, 32.3 % in RRT, and 58.0 % in
RRT + ECMO. Underlying co-morbidities were found in 3745 patients (78.1 %) who received ET (81 % for ECMO,
77.9 % in RRT, and 71.2 % in those who received both). There was a statistically significant increase in ECMO
utilization in patients with at least three organ dysfunctions from 2004 to 2012 (6.9 % versus 10.3 %, P < 0.001) while
RRT use declined (24.5 % versus 13.2 %, P < 0.001). After 2009, there was a significant increase in ECMO utilization
(3.6 % in 2004–2008 versus 4.0 % in 2009–2012, P = 0.004). ECMO and RRT were used simultaneously in only 500
patients with PSS (1 %).
Conclusions: ETs were used in a significant portion of PSS patients with multiple organ dysfunction syndrome
(MODS) during this time period. Mortality was significant and increased with increasing organ failure. ECMO use in
PSS patients with MODS increased from 2004 to 2012. Further evaluation of ET use in PSS is warranted.
Introduction
Since their inception, extracorporeal therapies (ETs) such
as extracorporeal membrane oxygenation (ECMO) and
renal replacement therapies (RRTs) have become more
widely available worldwide. ECMO for pediatric acute
respiratory distress syndrome [1] and RRT for renal failure
have become standards of treatment over the past decade.
However, current national utilization rates of these tech-
nologies in cases of pediatric septic shock (PSS) across US
children’s hospitals are still largely unknown.
PSS continues to be a leading cause of mortality and
morbidity in children [2, 3]. In recent years, there have
been significant strides made in sepsis treatment such as
the advent of goal-directed therapy [4] and the con-
sensus treatment guidelines published by the American
College of Critical Medicine (ACCM) [5]. Whereas adult
* Correspondence: amanda.ruth@choa.org
1Division of Pediatric Critical Care Medicine, Emory University School of
Medicine, 1405 Clifton Road NE, Atlanta, GA 30322, USA
2Department of Pediatrics, Emory University School of Medicine, 2015
Uppergate Drive, Atlanta, GA 30322, USA
Full list of author information is available at the end of the article
© 2015 Ruth et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ruth et al. Critical Care  (2015) 19:397 
DOI 10.1186/s13054-015-1105-4
studies have suggested variable outcomes for ECMO in
septic shock with survival rates ranging from 15 % to
70 % [6, 7], pediatric studies have been more promising.
A 2011 review of Extracorporeal Life Support Organiza-
tion data [8] suggested that survival rates have signifi-
cantly increased in cases of PSS as compared with initial
reports (an overall survival rate of 68 % versus 38.6 %)
[9]. Single-center experience suggests more satisfactory
outcomes in refractory PSS [10, 11]. The ACCM pediatric
sepsis guidelines were also revised in 2009 to recommend
consideration of ECMO in the event of refractory septic
shock [12].
Likewise, there are data that suggest potential benefits
of RRT use in certain populations [13]. Positive fluid
balance in critically ill children has been found to be an
independent risk factor for mortality in several studies,
and early institution of RRT is associated with an im-
proved outcome [14].
The objectives of this study are (a) to report utilization
rate of these technologies in patients with PSS in US
pediatric hospitals from 2004 to 2012, (b) analyze the
demographics and clinical characteristics of PSS patients
in whom ET was used, and (c) report outcomes and
trends in this particular PSS cohort.
Methods
Data collection
This was an observational, retrospective cohort review
of a prospectively collected research database. The study
was approved by institutional review boards from the
Children’s Hospital Association (CHA) (Overland Park,
KS, USA) and Children’s Healthcare of Atlanta. Require-
ment for informed consent was waived. All patient-
related data were de-identified prior to review and
enrollment.
Data were obtained from the Pediatric Health Infor-
mation System (PHIS) database, maintained by CHA,
which contains demographic, outcome, and resource
utilization data from 43 freestanding tertiary care chil-
dren’s hospitals (Additional file 1). Participating hospitals
are located in non-competing markets of 27 states plus
the District of Columbia and accounted for 15 % of all
pediatric hospitalizations in the US. The 43 hospitals in-
cluded in PHIS provide discharge data, including patient
demographics, diagnoses, and procedures. Billing data
include medications, radiologic imaging studies, labora-
tory tests, and supplies charged to each patient. Data are
de-identified prior to inclusion in the database; however,
encrypted medical record numbers allow tracking of in-
dividual patients across admissions. CHA and participat-
ing hospitals jointly ensure data integrity as previously
described [15, 16].
All children (0–18 years of age) admitted to a pediatric
intensive care unit (PICU) in the 43 participating hospitals
from January 2004 to December 2012 were identified
through an ICU admission flag in PHIS. We defined PSS
if patients met any of these criteria: (a) ICD-9 codes for
severe sepsis (995.92) or septic shock (785.52), (b) ICD-9
codes for infection and acute organ dysfunction (OD) as
previously defined by Angus et al. [17] and with codes
updated by Weiss et al. [18]. Those receiving ET were
further identified by individual flags for ECMO and RRT,
respectively. ECMO use was defined in PHIS by an ICD
procedure code of 39.65 or a clinical transaction code
(CTC) of 521181. RRT use was defined in PHIS as a CTC
of 525201 or 525221 [19]. Patients who had been admitted
to the neonatal intensive care unit (NICU) during the
same hospitalization (i.e., NICU patients subsequently
transferred to PICU) were excluded as PHIS does not have
the ability to distinguish whether a PSS episode or ET use
occurred in the NICU or the PICU.
Analysis was performed on data from all 43 participat-
ing children’s hospitals. For purposes of trend analysis,
we identified 33 hospitals that were CHA members
and contributed continuous data from the years 2004
to 2012.
Demographic data were reported on the basis of their
inclusion in the PHIS database. Age was divided into
grouping consistent with the US National Census Bur-
eau reporting. Underlying patient disease co-morbidities
were determined by using the definition of a Pediatric
Complex Chronic Condition [20]. Length of stay (LOS)
was reported as median with interquartile range (IQR)
being 25th and 75th percentiles. Hospitalization charges
were supplied by CHA as the total amount that was
charged to the patient by individual hospitals. Cost was
estimated by multiplying the total hospital charge by the
hospital-specific ratio of cost to charge. All reported fig-
ures were adjusted for inflation to the year 2012 by using
published US Bureau of Labor Statistics data for medical
cost inflation.
Statistical analysis
Statistical analyses were performed by using SAS 9.3
(SAS Institute Inc., Cary, NC, USA). Statistical signifi-
cance was assessed at the 0.05 level unless otherwise
noted. Descriptive statistics were calculated for all vari-
ables of interest. Chi-squared tests were used to compare
categorical variables, and two-sample t tests or Wilcoxon
rank-sum tests were used to compare continuous variables
between two groups or years. Although it was possible for
a patient to have multiple PICU admissions for severe sep-
sis over the 9-year cohort, such patients could not be
uniquely identified in the PHIS database. Thus, multiple
PICU admissions were treated as independent for the pur-
poses of statistical analyses. A generalized linear mixed
model was used to assess the effect of time on ET use in
patients with PSS while adjusting for OD and PSS cases
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clustered within hospitals. This model adjusts for the cor-
relation among PSS cases from the same hospital. Only
hospitals contributing consecutive data from 2004 to 2012
were included in the trend analysis (n = 33). Similar
models were used to examine the use of specific modal-
ities (i.e., ECMO and RRT) over time and to compare
odds of mortality among subgroups of patients with PSS
using ET.
Results
Utilization rate of extracorporeal therapies
In total, 636,482 PICU admissions were reported from
the 43 hospitals after excluding 2269 patients who had a
concurrent NICU admission during the same hospi-
talization. Among the PICU patients, 7.7 % (49,153 pa-
tients) met our definition of PSS. This PSS cohort was
analyzed further for ET utilization. In this group, 4795
(9.8 %) patients received at least one form of ET. RRT was
the more commonly used modality (7.0 %), followed by
ECMO (3.8 %) (Table 1). Among patients receiving ET, few
received both ET modalities (500 patients, 1.0 %) (Table 2).
ET utilization was higher in PSS patients with multiple
organ dysfunction syndrome (MODS) defined as OD of
at least 3. Among these patients (8310 patients, 16.9 %
of the PSS cohort), 2047 (24.6 %) received at least one
ET modality. ECMO use was seen in 8.9 % of PSS
Table 1 Demographics of patients with pediatric severe sepsis on extracorporeal therapy
All patients from 2004 to 2012 Any ET ECMO RRT
N = 49,153 PSS cases
Use in PSS, N (%) 4795 (9.8 %) 1858 (3.8 %) 3437 (7.0 %)
Gender, N (%)
Male 2452 (51.2 %) 978 (52.7 %) 1728 (50.3 %)
Female 2342 (48.8 %) 879 (47.3 %) 1709 (49.7 %)
Age group at admission, N (%)
<1 year 1198 (25.0 %) 830 (44.7 %) 537 (15.6 %)
1–4 years 1102 (23.0 %) 421 (22.7 %) 783 (22.8 %)
5–9 years 657 (13.7 %) 192 (10.3 %) 531 (15.5 %)
10–18 years 1838 (38.3 %) 415 (22.3 %) 1586 (46.1 %)
Total hospitalization, days
Median (25 %–75 %) 34 (17–64) 35 (16–67) 34 (17–62)
ICU, days
Median (25 %–75 %) 19 (8–38) 25 (12–48) 17 (7–34)
Co-morbidities, N (%)
Any condition 3745 (78.1 %) 1,456 (78.4 %) 2645 (77.0 %)
Neurologic 580 (12.1 %) 198 (10.7 %) 424 (12.3 %)
Cardiovascular 1734 (36.2 %) 1119 (60.2 %) 849 (24.7 %)
Respiratory 263 (5.5 %) 156 (8.4 %) 141 (4.1 %)
Renal 767 (16.0 %) 92 (5.0 %) 708 (20.6 %)
Gastroenterology 304 (6.3 %) 64 (3.4 %) 258 (7.5 %)
Hematology/Immunology 452 (9.4 %) 139 (7.5 %) 347 (10.1 %)
Metabolic disorder 976 (20.4 %) 207 (11.1 %) 844 (24.6 %)
Malignancy 855 (17.8 %) 133 (7.1 %) 773 (22.5 %)
Other 417 (8.7 %) 216 (11.6 %) 234 (6.8 %)
Acute organ dysfunction
Number of systems affected, N (%)
1 969 (20.2 %) 286 (15.4 %) 728 (21.2 %)
2 1779 (37.1 %) 831 (44.7 %) 1133 (33.0 %)
3 1187 (24.8 %) 462 (24.9 %) 878 (25.6 %)
4 611 (12.7 %) 205 (11.0 %) 494 (14.4 %)
5+ 249 (5.2 %) 74 (4.0 %) 204 (5.9 %)
PSS pediatric severe sepsis, ET extracorporeal therapy, ECMO extracorporeal membrane oxygenation, RRT Renal replacement therapy
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patients with MODS, whereas RRT was used in 19.0 %
of this patient population.
Clinical demographics
Overall, ET use in patients with PSS was divided equally
among gender; 51 % of those receiving any ET were
male and 49 % were female. Patients less than 1 year of
age accounted for the majority of those receiving only
ECMO (48.7 %) (Table 3). This subgroup also accounted
for the majority of patients receiving both modalities,
representing 169 (33.8 %) of patients who received both
ECMO + RRT.
RRT alone was most common in children 10–18 years
old (48.5 %). Patients who received any form of ET had
a prolonged hospitalization with median hospital LOS
(length of stay) of 34 days (IQR of 17–64 days) and
PICU LOS of 19 days (IQR of 8–38 days) (Table 1).
Co-morbidity and organ dysfunction
A significant proportion of PSS patients receiving ET
have at least one underlying co-morbidity (78.1 %) com-
pared with the baseline of 73.8 % in the general PSS









Prevalence (N = 49,153) 1358 (2.3 %) 2937 (6.0 %) 500 (1.0 %)
Gender, N (%)
Male 724 (53.4 %) 1474 (50.2 %) 254 (50.8 %)
Female 633 (46.6 %) 1463 (49.8 %) 246 (49.2 %)
Mortality, N (%) 649 (47.8 %) 948 (32.3 %) 290 (58.0 %)
Age group at admission 1.1 (0.2–6.7) 9.6 (2.6–14.8) 3.9 (0.4–12.8)
Median (25 %–75 %)
Total hospitalization, days 34 (17–69) 33 (17–62) 36 (16–60)
Median (25 %–75 %)
ICU, days 24 (12–49) 16 (6–32) 27 (12–46)
Median (25 %–75 %)
ECMO extracorporeal membrane oxygenation, RRT Renal replacement therapy,
ICU intensive care unit
Table 3 Prevalence of extracorporeal therapy use and mortality by age, co-morbidity, and organ dysfunction
Characteristic ECMO alone (N = 1358) RRT alone (N = 2937) ECMO + RRT (N = 500)
Prevalence Mortality Prevalence Mortality Prevalence Mortality
Age
<1 year 661 (48.7 %) 344 (52.0 %) 368 (12.5 %) 144 (39.1 %) 169 (33.8 %) 111 (65.7 %)
1-4 years 319 (23.5 %) 130 (40.8 %) 681 (23.2 %) 197 (28.9 %) 102 (20.4 %) 61 (59.8 %)
5-9 years 126 (9.3 %) 57 (45.2 %) 465 (15.8 %) 133 (28.6 %) 66 (13.2 %) 27 (40.9 %)
10-18 years 252 (18.6 %) 118 (46.8 %) 1423 (48.5 %) 474 (33.3 %) 163 (32.6 %) 91 (55.8 %)
Co-morbidity
Any condition 1100 (81.0 %) 522 (47.5 %) 2289 (77.9 %) 806 (35.2 %) 356 (71.2 %) 206 (71.0 %)
Neurologic 156 (11.5 %) 57 (36.5 %) 382 (13.0 %) 113 (29.6 %) 42 (8.4 %) 21 (50.0 %)
Cardiovascular 885 (65.2 %) 404 (45.7 %) 615 (20.9 %) 261 (42.4 %) 234 (46.8 %) 135 (57.7 %)
Respiratory 122 (9.0 %) 50 (41.0 %) 107 (3.6 %) 52 (48.6 %) 34 (6.8 %) 25 (73.5 %)
Renal 59 (4.3 %) 31 (52.5 %) 675 (23.0 %) 129 (13.6 %) 33 (6.6 %) 18 (54.6 %)
Gastroenterology 46 (3.4 %) 23 (50.0 %) 240 (8.2 %) 107 (44.6 %) 18 (3.6 %) 13 (72.2 %)
Hematology/Immunology 105 (7.7 %) 57 (54.3 %) 313 (10.7 %) 144 (15.2 %) 34 (6.8 %) 21 (61.8 %)
Metabolic disorder 132 (9.7 %) 61 (46.2 %) 769 (26.2 %) 210 (27.3 %) 75 (15.0 %) 38 (50.7 %)
Malignancy 82 (6.0 %) 52 (63.4 %) 723 (24.6 %) 381 (52.7 %) 50 (10.0 %) 29 (58.0 %)
Other 183 (13.5 %) 94 (51.4 %) 201 (6.8 %) 63 (31.3 %) 33 (6.6 %) 22 (66.7 %)
None 258 (19.0 %) 127 (49.2 %) 648 (22.1 %) 142 (21.9 %) 144 (28.8 %) 84 (58.3 %)
Organ dysfunction
1 241 (17.8 %) 122 (50.6 %) 683 (23.3 %) 82 (12.0 %) 45 (9.0 %) 27 (60.0 %)
2 646 (47.6 %) 264 (40.9 %) 948 (32.3 %) 299 (31.5 %) 185 (37.0 %) 102 (55.1 %)
3 309 (22.8 %) 163 (52.8 %) 725 (24.7 %) 302 (41.7 %) 153 (30.6 %) 89 (58.2 %)
4 117 (8.6 %) 72 (61.5 %) 406 (13.8 %) 182 (44.8 %) 88 (17.6 %) 52 (59.1 %)
5+ 45 (3.3 %) 28 (62.2 %) 175 (6.0 %) 83 (47.4 %) 29 (5.8 %) 20 (69.0 %)
ECMO extracorporeal membrane oxygenation, RRT Renal replacement therapy
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cohort [2]. Underlying cardiovascular dysfunction was
the most common co-morbidity found in patients
receiving ECMO alone (65.2 %). A cardiovascular co-
morbidity also was the most common underlying condi-
tion in those receiving combination therapies (46.8 % of
those receiving ECMO + RRT). The most common co-
morbidities found in patients receiving RRT alone were
metabolic disorder (26.2 %) and malignancy (24.6 %),
ahead of renal causes (23.0 %) (Table 3).
The majority of PSS patients who were placed on ET
had at least two organs with dysfunction (OD), account-
ing for 79.8 % patients of PSS patients on ET. ET use
was associated with the presence of MODS. MODS was
present in 42.7 % of PSS patients receiving ET but in
only 14.1 % of PSS patients who did not receive ET.
Mortality
Overall mortality rate in PSS patients who received ET
was 39.4 % (1887 patients). Mortality rates were 47.8 % in
PSS patients receiving ECMO alone (n = 649), 32.3 % in
those receiving RRT alone (n = 2937), and 58.0 % in those
receiving both ECMO and RRT (n = 500) (Table 2).
Among PSS patients receiving ECMO alone, patients less
than 1 year of age had the highest rate of mortality (344
out of 661 patients, or 52.0 %). In patients receiving only
RRT, mortality was also highest in those less than 1 year
of age (144 out of 368 patients, or 39.1 %) (Table 3).
Patients with malignancy had the highest mortality rate
(462 patients, or 54.0 %) out of those who received any
form of ET, ECMO alone (52 out of 82 patients, or 63.4 %),
and RRT alone (381 out of 723 patients, or 52.7 %).
PSS patients under 1 year of age represented the largest
proportion of patients receiving multiple ET modalities:
they account for 33.8 % of patients who received ECMO
+RRT (169 out of 500 patients). They also had the highest
mortality rate (65.7 %). In patients with MODS receiving
ET, mortality was high (48.4 %). Mortality was higher in
patients receiving ECMO (47.8 %) compared with those
on RRT (32.3 %) (P < 0.001). Odds of mortality increased
sequentially with increasing OD. PSS patients on ET with
severe OD (≥5) had higher odds of mortality compared
with patients on ET with one OD (OR = 3.60, 95 % CI
2.68–4.84, P <0.001). The highest mortality rate in pa-
tients with MODS was among those who received both
ET modalities (161 out of 270, or 59.6 %).
Trends
ET usage overall in patients with PSS significantly
decreased over time (13.3 % in 2004 % to 7 % in 2012 %,
P < 0.001); however, patterns of use for specific modal-
ities over time are not consistent. Across all patients, the
rate of ECMO utilization remained steady from 2004 to
2008 but showed moderate increases from 2008 to 2012.
After adjustment for cases from the same hospital and
severity of OD, patients with PSS from 2009 to 2012 had
higher odds of receiving ECMO compared with pa-
tients from 2004 to 2008 (OR = 1.18, 95 % CI 1.06–1.33,
P = 0.004). In contrast, there was a significant decrease in
RRT over time (Fig. 1, P < 0.001). We performed add-
itional analysis to determine the impact of specific co-
morbidities. ECMO utilization significantly increased in
PSS patients with malignancy co-morbidities over the 9-
year period (4.5 % in 2004 to 9.0 % in 2012). However,
after removal of this small number of patients with malig-
nancies, the odds of receiving ECMO for patients with
PSS remained unchanged and was still higher for patients
in the 2009–2012 versus the 2004–2008 time periods
(OR = 1.18, 95 % CI 1.05–1.33).
Patients with PSS from 2009 to 2012 had lower odds
of receiving RRT compared with patients from 2004 to
2009 (OR = 0.64, 95 % CI 0.59–0.69, P < 0.001). Exclud-
ing the malignancy population changed the odds to 0.60
(95 % CI 0.55–0.66, P < 0.001).
When RRT use in patients with MODS was examined
(Fig. 2), rates also significantly declined (P < 0.001) dur-
ing the same time intervals. Odds of receiving RRT in
PSS MODS patients decreased by 27 % from 2009 to
2012 compared with 2004 to 2008 (OR = 0.72, 95 % CI
0.63– 0.83). In contrast, ECMO rates increased over
time (Fig. 2, P = 0.001), and the odds of receiving ECMO
in PSS patients with MODS was 1.5 times higher from
2009 to 2012 compared with 2004 to 2008 (95 % CI
1.24–1.80, P <0.001).
In this cohort of PSS patients on ET, yearly mortality
rates showed small decreases over time (41.9 % in 2004
versus 36.3 % in 2012); however, odds of mortality
decreased by only 6 % per year (OR = 0.94, 95 % CI
0.93–0.95, P < 0.001). A similar trend was observed in
mortality in PSS patients specifically receiving ECMO
(Fig. 1). Odds of mortality decreased by 7 % per year
(OR = 0.93, 95 % CI 0.90–0.97, P < 0.001). For PSS pa-
tients with malignancy on ECMO, the mortality odds
had a more substantial drop of 21 % per year (OR = 0.79,
95 % CI 0.66–0.95, P = 0.011).
A similar, but less pronounced, trend in mortality was
observed in overall PSS patients receiving RRT with
odds of mortality decreasing by 4 % per year (OR = 0.96,
95 % CI (0.93–0.99, P = 0.008). In PSS patients with
malignancy receiving RRT (n = 648), the odds signifi-
cantly decreased over time (OR = 0.90, 95 % CI 0.84–
0.95, P < 0.001). Overall in PSS patients with MODS on
ET, mortality also decreased from 2004 to 2012 (56.8 % to
48.5 %), but odds of mortality decreased by only 4 % per
year (OR = 0.96, 95 % CI 0.93–0.999, P = 0.0439).
In patients receiving ET in our 10-year cohort (n = 4795),
median (25 %–75 %) hospitalization cost was $270,778
($122,506–$528,732) and significantly higher compared
with median cost of $69,070 ($29,931–$155,864) in PSS
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patients who did not receive any ET. When accounting
for LOS, median cost per day was 1.8 times higher in pa-
tients receiving ET compared with those who did not
($7,591 versus $4,334). In hospitals with data over the
entire 10-year period for PSS (n = 33 hospitals), there
was a significant negative relationship between center
volume and mortality for patients on ECMO (rs = −0.43,
95 % CI −0.67 to −0.09, P = 0.013); that is, mortality
decreased with increasing center volume of ECMO
cases.
Discussion
In this largest reported analysis of ET utilization in PSS
to date, overall rates were relatively consistent through-
out the time period studied. However, we did find that
in a time period coinciding with publication of the 2009
ACCM guidelines for severe sepsis management with
revised recommendations of ECMO consideration for
refractory PSS, ECMO utilization significantly increased,
especially in PSS patients with MODS (10 % from 2009
to 2012 versus 7 % in 2004 to 2008).
Fig. 1 Top: the solid line represents the prevalence of ECMO use in the patients with PSS. The broken line represents mortality rate in PSS patients
who received ECMO. *indicates a significant increase in the prevalence of patients receiving ECMO. **indicates a significant decrease in mortality
over time. Bottom: the solid line represents RRT use in the overall PSS patient population. The broken line represents mortality rate over time in the
patients with PSS. ECMO extracorporeal membrane oxygenation, PSS pediatric severe sepsis, RRT Renal replacement therapy
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Excluding primary NICU patients, children under 1 year
old continue to represent a disproportionately large per-
centage of those receiving ECMO. Although our data did
not allow us to further analyze the root cause of this, pos-
sible explanations include the prevalence of congenital
conditions (i.e., congenital heart disease, neurological mal-
formation, etc.) in this population and history of prema-
turity with multiple accompanying medical conditions.
Associated cardiovascular co-morbidity was found in a
large percentage of all patients receiving ECMO and rep-
resents a significant proportion of PSS patients receiving
multiple modalities. This may be because ECMO is used
more commonly in cardiac patients compared with gen-
eral medical patients. As might be expected, degree of OD
impacted use of ET. Children with at least three ODs had
a significantly higher proportion of ET utilization than
those with fewer ODs. This held true when analyzing
those who received ECMO and RRT separately (34.7 % of
those receiving ECMO, 44.5 % of those receiving RRT,
and 54.0 % receiving both had at least three ODs).
We previously reported that overall PSS mortality has
been declining with increasing prevalence since 2004 [2].
Mortality was high in PSS patients who received ET, re-
flective of the greater severity of illness of these patients.
Fig. 2 Top: the solid line represents the prevalence of ECMO use in PSS patients with MODS. The broken line represents the mortality rate of
MODS patients on ECMO. *indicates a significant increase in the utilization of ECMO in PSS patients with MODS. Bottom: the solid line represents
the prevalence of RRT use in PSS patients with MODS. The broken line represents mortality rate in MODS patients who received RRT. ECMO
extracorporeal membrane oxygenation, MODS multiple organ dysfunction syndrome, PSS pediatric severe sepsis, RRT Renal replacement therapy
Ruth et al. Critical Care  (2015) 19:397 Page 7 of 9
The overall mortality of PSS patients on RRT was 32.3 %
in our study. The overall ECMO mortality rate of 47.8 %
is comparable to recently published reports of a 40 % mor-
tality rate in ECMO patients with acute respiratory dis-
tress syndrome secondary to sepsis [21]. For PSS patients
receiving both RRT and ECMO, the mortality was even
higher at 60 %. Despite these high rates, we found a sig-
nificant improvement over time in overall survival in pa-
tients receiving ECMO. This was more pronounced in the
population of PSS patients with malignancy, whose mor-
tality odds went down substantially over the periods of the
study. Similar trends were seen in mortality rates for ma-
lignancy patients receiving RRT, with lower mortality odds
over time as well.
The improvement in survival rate was associated with
a tendency for improved outcomes in higher-volume
ECMO centers. Improved outcomes in ECMO and RRT
patients with malignancy are in line with reports of im-
proved outcomes on ECMO with conditions such as can-
cer previously thought to be contraindications to ECMO
use [22].
Our study has several limitations in addition to its re-
spective nature. The administrative nature of the PHIS
database, which has billing and resource utilization data
but is missing some important clinical parameters, limits
the ability to make better clinical correlations. Thus, we
were unable to assess some variables that may have been
clinically significant, such as whether a patient was
placed on veno-arterial versus veno-venous ECMO. An-
other major limitation is the lack of variables needed to
calculate a severity-of-illness score. While we used OD
as a surrogate, detailed clinical data to calculate PRISM-
III (The Pediatric Risk of Mortality III) or PELOD
(Pediatric Logistic Organ Dysfunction) scores are not
available in PHIS. Because data are derived from ICD-9
codes collected throughout hospitalization, we were also
unable to determine whether death occurred while a pa-
tient was undergoing an ET or afterwards. Hospitals in
the PHIS database are generally tertiary or quaternary
referral centers and treat more medically complex pa-
tients than other community-based pediatric facilities
that are not represented in PHIS. This may limit
generalization of conclusions drawn from studying PHIS
centers. Finally, reported mortality reported is all-cause
mortality. A patient who survived the initial sepsis epi-
sode could have expired from another cause later during
the hospitalization, but the data do not allow one to dis-
tinguish between causes of death. This limits absolute
conclusions regarding mortality and ET use.
Conclusions
In this large multicenter PSS PICU cohort, ECMO use
in PSS significantly increased since 2009. There was a
similarly significant increase in ECMO utilization after
2009 in patients with MODS. This may have been re-
lated to increasing support in the literature on successful
use of ECMO in patients with co-morbidities as well as
recommendations in the ACCM sepsis guidelines sup-
porting ECMO consideration. Mortality rates in PSS pa-
tients receiving ECMO decreased over time and are
comparable to the latest nationally published pediatric
sepsis outcome data. In PSS patients with malignancy,
there is a statistically significant improvement in survival
rate for those placed on ECMO and RRT. Further re-
search with more clinically robust data is needed to de-
termine the impact of different ET modalities in the PSS
patient population.
Key messages
 PSS remains a relevant health issue in the US
pediatric population. ET utilization in this cohort
has not been adequately described.
 ECMO and RRT were used in a small percentage of
children with PSS, with a higher rate of utilization in
PSS patients with MODS.
 From 2004 through 2012, overall utilization of ET in
patients with PSS remained relatively unchanged.
However, ECMO use significantly increased after
2009, especially in patients with MODS.
 Mortality rates in PSS patients receiving ECMO and
RRT were consistent with previously published
reports; survival improved over the time period in
PSS patients receiving ECMO.
 ET can provide potentially beneficial adjunctive
treatment in patients with PSS. Further research and
clinical correlation to these epidemiologic findings
are warranted.
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